165 related articles for article (PubMed ID: 35387752)
1. Concurrent Cetuximab-based bioradiotherapy versus Cisplatin-based Chemoradiotherapy in the Definitive Management of Favourable Biology Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma: Systematic Review and Meta-analysis.
Swain M; Kannan S; Srinivasan S; Agarwal JP; Gupta T
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):786-795. PubMed ID: 35387752
[TBL] [Abstract][Full Text] [Related]
2. Systematic evaluation and meta-analysis of the prognosis of down-staging human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma using cetuximab combined with radiotherapy instead of cisplatin combined with radiotherapy.
Hu Q; Li F; Yang K
PeerJ; 2024; 12():e17391. PubMed ID: 38784388
[TBL] [Abstract][Full Text] [Related]
3. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H; Robinson M; Hartley A; Kong A; Foran B; Fulton-Lieuw T; Dalby M; Mistry P; Sen M; O'Toole L; Al Booz H; Dyker K; Moleron R; Whitaker S; Brennan S; Cook A; Griffin M; Aynsley E; Rolles M; De Winton E; Chan A; Srinivasan D; Nixon I; Grumett J; Leemans CR; Buter J; Henderson J; Harrington K; McConkey C; Gray A; Dunn J;
Lancet; 2019 Jan; 393(10166):51-60. PubMed ID: 30449623
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
Gillison ML; Trotti AM; Harris J; Eisbruch A; Harari PM; Adelstein DJ; Jordan RCK; Zhao W; Sturgis EM; Burtness B; Ridge JA; Ringash J; Galvin J; Yao M; Koyfman SA; Blakaj DM; Razaq MA; Colevas AD; Beitler JJ; Jones CU; Dunlap NE; Seaward SA; Spencer S; Galloway TJ; Phan J; Dignam JJ; Le QT
Lancet; 2019 Jan; 393(10166):40-50. PubMed ID: 30449625
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE.
Suton P; Skelin M; Rakusic Z; Dokuzovic S; Luksic I
Eur Arch Otorhinolaryngol; 2019 May; 276(5):1275-1281. PubMed ID: 30887169
[TBL] [Abstract][Full Text] [Related]
7. Paired phase II trials evaluating cetuximab and radiotherapy for low risk HPV associated oropharyngeal cancer and locoregionally advanced squamous cell carcinoma of the head and neck in patients not eligible for cisplatin.
Swiecicki PL; Li P; Bellile E; Stucken C; Malloy K; Shuman A; Spector ME; Chinn S; Casper K; McLean S; Moyer J; Chepeha D; Wolf GT; Prince M; Bradford C; Nyati M; Eisbruch A; Worden FP; Jolly S; Mierzwa M
Head Neck; 2020 Aug; 42(8):1728-1737. PubMed ID: 31989702
[TBL] [Abstract][Full Text] [Related]
8. Chemoradiotherapy in Human Papillomavirus-associated Oropharyngeal Squamous Cell Carcinoma. Cetuximab is Inferior to Cisplatin - is the Case now Closed?
Donnelly O; Kelly C; Iqbal MS
Clin Oncol (R Coll Radiol); 2022 Dec; 34(12):783-785. PubMed ID: 35945073
[No Abstract] [Full Text] [Related]
9. Determining optimal follow-up in the management of human papillomavirus-positive oropharyngeal cancer.
Frakes JM; Naghavi AO; Demetriou SK; Strom TJ; Russell JS; Kish JA; McCaffrey JC; Otto KJ; Padhya TA; Harrison LB; Trotti AM; Caudell JJ
Cancer; 2016 Feb; 122(4):634-41. PubMed ID: 26565997
[TBL] [Abstract][Full Text] [Related]
10. De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
Howard J; Dwivedi RC; Masterson L; Kothari P; Quon H; Holsinger FC
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012939. PubMed ID: 30550641
[TBL] [Abstract][Full Text] [Related]
11. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
[TBL] [Abstract][Full Text] [Related]
12. Prognostic stratification of HPV-associated oropharyngeal cancer based on CD103
Rischin D; Mehanna H; Young RJ; Bressel M; Dunn J; Corry J; Soni P; Fulton-Lieuw T; Iqbal G; Kenny L; Porceddu S; Wratten C; Robinson M; Solomon BJ;
Ann Oncol; 2022 Aug; 33(8):804-813. PubMed ID: 35525376
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin versus cetuximab with definitive concurrent radiotherapy for head and neck squamous cell carcinoma: An analysis of Veterans Health Affairs data.
Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Di Stefano J; Knepley C; Limaye S; Mamtani R; Wisnivesky J; Damjanov N; Langer CJ; Cohen RB; Sigel K
Cancer; 2019 Feb; 125(3):406-415. PubMed ID: 30341983
[TBL] [Abstract][Full Text] [Related]
14. De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
Patel RR; Ludmir EB; Augustyn A; Zaorsky NG; Lehrer EJ; Ryali R; Trifiletti DM; Adeberg S; Amini A; Verma V
Oral Oncol; 2020 Apr; 103():104608. PubMed ID: 32163853
[TBL] [Abstract][Full Text] [Related]
15. Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis.
Huang J; Zhang J; Shi C; Liu L; Wei Y
BMC Cancer; 2016 Aug; 16(1):689. PubMed ID: 27565887
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study.
Rischin D; King M; Kenny L; Porceddu S; Wratten C; Macann A; Jackson JE; Bressel M; Herschtal A; Fisher R; Fua T; Lin C; Liu C; Hughes BGM; McGrath M; McDowell L; Corry J
Int J Radiat Oncol Biol Phys; 2021 Nov; 111(4):876-886. PubMed ID: 34098030
[TBL] [Abstract][Full Text] [Related]
17. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
18. Association of Human Papillomavirus and p16 Status With Outcomes in the IMCL-9815 Phase III Registration Trial for Patients With Locoregionally Advanced Oropharyngeal Squamous Cell Carcinoma of the Head and Neck Treated With Radiotherapy With or Without Cetuximab.
Rosenthal DI; Harari PM; Giralt J; Bell D; Raben D; Liu J; Schulten J; Ang KK; Bonner JA
J Clin Oncol; 2016 Apr; 34(12):1300-8. PubMed ID: 26712222
[TBL] [Abstract][Full Text] [Related]
19. Subgroup Analysis According to Human Papillomavirus Status and Tumor Site of a Randomized Phase II Trial Comparing Cetuximab and Cisplatin Combined With Radiation Therapy for Locally Advanced Head and Neck Cancer.
Buglione M; Maddalo M; Corvò R; Pirtoli L; Paiar F; Lastrucci L; Stefanacci M; Belgioia L; Crociani M; Vecchio S; Bonomo P; Bertocci S; Borghetti P; Pasinetti N; Triggiani L; Costa L; Tonoli S; Grisanti S; Magrini SM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):462-472. PubMed ID: 27986347
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy.
Adrian G; Forslund O; Pedersen L; Sjövall J; Gebre-Medhin M
Radiother Oncol; 2023 Sep; 186():109773. PubMed ID: 37385383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
